Advanced

Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma

Barrington, Sally F.; Qian, Wendi; Somer, Edward J.; Franceschetto, Antonella; Bagni, Bruno; Brun, Eva LU ; Almquist, Helen; Loft, Annika; Hojgaard, Liselotte and Federico, Massimo, et al. (2010) In European Journal of Nuclear Medicine and Molecular Imaging 37(10). p.1824-1833
Abstract
To determine if PET reporting criteria for the Response Adapted Treatment in Hodgkin Lymphoma (RATHL) trial could enable satisfactory agreement to be reached between 'core' laboratories operating in different countries. Four centres reported scans from 50 patients with stage II-IV HL, acquired before and after two cycles of Adriamycin/bleomycin/vinblastine/dacarbazine. A five-point scale was used to score response scans using 'normal' mediastinum and liver as reference levels. Centres read scans independently of each other. The level of agreement between centres was determined assuming (1) that uptake in sites involved at diagnosis that was higher than liver uptake represented disease (conservative reading), and (2) that uptake in sites... (More)
To determine if PET reporting criteria for the Response Adapted Treatment in Hodgkin Lymphoma (RATHL) trial could enable satisfactory agreement to be reached between 'core' laboratories operating in different countries. Four centres reported scans from 50 patients with stage II-IV HL, acquired before and after two cycles of Adriamycin/bleomycin/vinblastine/dacarbazine. A five-point scale was used to score response scans using 'normal' mediastinum and liver as reference levels. Centres read scans independently of each other. The level of agreement between centres was determined assuming (1) that uptake in sites involved at diagnosis that was higher than liver uptake represented disease (conservative reading), and (2) that uptake in sites involved at diagnosis that was higher than mediastinal uptake represented disease (sensitive reading). There was agreement that the response scan was 'positive' or 'negative' for lymphoma in 44 patients with a conservative reading and in 41 patients with a sensitive reading. Kappa was 0.85 (95% CI 0.74-0.96) for conservative reading and 0.79 (95% CI 0.67-0.90) for sensitive reading. Agreement was reached in 46 and 44 patients after discussion for the conservative and sensitive readings, respectively. The criteria developed for reporting in the RATHL trial are sufficiently robust to be used in a multicentre setting. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Quality control/quality, Positron emission tomography, Hodgkin lymphoma, assurance, Clinical trial
in
European Journal of Nuclear Medicine and Molecular Imaging
volume
37
issue
10
pages
1824 - 1833
publisher
Springer
external identifiers
  • wos:000281597700003
  • scopus:79952114063
ISSN
1619-7070
DOI
10.1007/s00259-010-1490-5
language
English
LU publication?
yes
id
d8865c68-c4e6-4a94-9691-311edf63247a (old id 1697746)
date added to LUP
2010-10-22 16:13:26
date last changed
2018-07-15 03:02:15
@article{d8865c68-c4e6-4a94-9691-311edf63247a,
  abstract     = {To determine if PET reporting criteria for the Response Adapted Treatment in Hodgkin Lymphoma (RATHL) trial could enable satisfactory agreement to be reached between 'core' laboratories operating in different countries. Four centres reported scans from 50 patients with stage II-IV HL, acquired before and after two cycles of Adriamycin/bleomycin/vinblastine/dacarbazine. A five-point scale was used to score response scans using 'normal' mediastinum and liver as reference levels. Centres read scans independently of each other. The level of agreement between centres was determined assuming (1) that uptake in sites involved at diagnosis that was higher than liver uptake represented disease (conservative reading), and (2) that uptake in sites involved at diagnosis that was higher than mediastinal uptake represented disease (sensitive reading). There was agreement that the response scan was 'positive' or 'negative' for lymphoma in 44 patients with a conservative reading and in 41 patients with a sensitive reading. Kappa was 0.85 (95% CI 0.74-0.96) for conservative reading and 0.79 (95% CI 0.67-0.90) for sensitive reading. Agreement was reached in 46 and 44 patients after discussion for the conservative and sensitive readings, respectively. The criteria developed for reporting in the RATHL trial are sufficiently robust to be used in a multicentre setting.},
  author       = {Barrington, Sally F. and Qian, Wendi and Somer, Edward J. and Franceschetto, Antonella and Bagni, Bruno and Brun, Eva and Almquist, Helen and Loft, Annika and Hojgaard, Liselotte and Federico, Massimo and Gallamini, Andrea and Smith, Paul and Johnson, Peter and Radford, John and O'Doherty, Michael J.},
  issn         = {1619-7070},
  keyword      = {Quality control/quality,Positron emission tomography,Hodgkin lymphoma,assurance,Clinical trial},
  language     = {eng},
  number       = {10},
  pages        = {1824--1833},
  publisher    = {Springer},
  series       = {European Journal of Nuclear Medicine and Molecular Imaging},
  title        = {Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma},
  url          = {http://dx.doi.org/10.1007/s00259-010-1490-5},
  volume       = {37},
  year         = {2010},
}